MedTrace Logo

A Study of CS1002 in Subjects with Advanced Solid Tumors

NCT03523819 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2024-09-19

No results posted yet for this study

Summary

This is a multicenter, open-label, multiple dose, dose escalation phase I study to evaluate the clinical safety, tolerability, PK, and preliminary anti-tumor efficacy of CS1002.

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

CS1002

Dose levels will be escalated following a modified 3+3 dose escalation scheme

DRUG

CS1003

Fixed dose at 200mg in combination with CS1002 on a specified dose level

Sponsors & Collaborators

Principal Investigators

  • Wanmei Wang · CStone Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-26
Primary Completion
2022-01-18
Completion
2022-01-18

Countries

  • Australia
  • Hong Kong

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03523819 on ClinicalTrials.gov